HRMY Holds $510M Net Cash as Market Prices Out Pipeline
Harmony Biosciences just reaffirmed its full-year guidance on the heels of a 30.5% Q2 earnings beat, while sitting on $670 million in cash and running five active Phase 2 and Phase 3 clinical programs
HRMY Holds $510M Net Cash as Market Prices Out Pipeline
NEW YORK, September 5 —
Harmony Biosciences Holdings, Inc. (HRMY) just posted its largest earnings beat in four quarters and reaffirmed full-year guidance, yet the stock trades at 6.3 times forward earnings, a multiple that assigns near-zero value to five active clinical programs and $510 million in net cash.
- Q2 2026 EPS $1.50 vs. $1.15 consensus, 30.5% positive surprise; full-year guidance reaffirmed. (8-K, Aug. 4)
- $670M cash, $160M debt; $183M trailing free cash flow funds five active pipeline programs without equity issuance.
- Forward P/E 6.3x on $2.46B market cap; 9.5% of float short.
Earnings Consistency Is the Short Thesis
Q2's beat is one swing in a volatile earnings history. Q3 2025 beat consensus by 25.5%, then Q4 2025 missed by 46.9%, with actual EPS of $0.57 against the $1.07 estimate, followed by Q1 2026's 16% shortfall. That beat-miss-miss-beat pattern across four quarters has kept short interest elevated at 9.5% of float. Reaffirming full-year guidance after Q2's positive surprise narrows near-term uncertainty; whether it signals a durable change in execution or another turn in the cycle, Q3 2026 results will tell.
WAKIX Funds Five Programs Off Its Own Cash Flow
WAKIX (pitolisant) is HRMY's sole commercial product, a narcolepsy therapy with a mechanism distinct from existing treatments, generating $0.96 billion in trailing revenue at 30.3% growth and 75.4% gross margins. Those economics fund five pipeline programs: pitolisant in Phase 3 for Prader-Willi Syndrome and Phase 2 for Myotonic Dystrophy Type 1; ZYN-002 in Phase 3 for Fragile X Syndrome; earlier programs target 22q Deletion Syndrome and narcolepsy via an orexin 2 receptor agonist. With $670 million in cash against $160 million in debt, the balance sheet funds the pipeline without dilution. Run a DCF calculator on WAKIX alone to see what the current multiple implies.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HRMY | $2.5B | 6.3x | +17.9% |
| KYMR | $9.7B | n/a | +171.1% |
| INBX | $1.8B | n/a | +316.4% |
| KROS | $224M | n/a | -28.2% |
| PCVX | $9.1B | n/a | +88.7% |
| RLAY | $4.2B | n/a | +368.2% |
Phase 3 Readouts Are the Valuation Catalyst
The debate over HRMY's 6.3x forward multiple resolves on clinical data, not earnings guidance. A positive Phase 3 readout for pitolisant in Prader-Willi Syndrome or for ZYN-002 in Fragile X Syndrome would force the market to price pipeline optionality it currently ignores; a failure in either would validate the skeptics. An executive's reported plan to sell approximately $230,000 in stock, per news reports, has not been confirmed in a Form 4 filing. The consensus analyst target of $47.36 sits above the current $42.25 share price; Q3 2026 results are the next earnings checkpoint. Run the free Harmony Biosciences Holdings, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Harmony Biosciences just reaffirmed its full-year guidance on the heels of a 30.5% Q2 earnings beat, while sitting on $670 million in cash and running five active Phase 2 and Phase 3 clinical programs — yet the stock trades at 6.3 times forward earnings with nearly one in ten shares sold short.